Cost-effectiveness of LTBI treatment for TB contacts in British Columbia

Value Health. Sep-Oct 2008;11(5):842-52. doi: 10.1111/j.1524-4733.2008.00334.x. Epub 2008 Jul 15.


Background: Contacts of patients with active tuberculosis ("TB contacts") with a tuberculin skin test (TST) size > or = 5 mm are currently recommended treatment for latent TB infection (LTBI). Knowing the cost-effectiveness of LTBI therapy for specific TB contact subpopulations may improve the use of limited resources by reducing the treatment of persons at low TB risk.

Objective: To evaluate the cost-effectiveness of LTBI therapy for different TB contact populations defined by important risk factors, and to propose an optimal policy based on different recommendation for each subgroup of contacts.

Methods: A 6-year Markov decision analytic model simulating the quality-adjusted life years (QALYs), number of active TB cases prevented, and costs for hypothetical cohorts of Canadian TB contacts defined by TST size, age group (< 10 y/o or above), ethnicity, closeness of contact, and Bacillus Calmette-Guérin (BCG) vaccination status.

Results: For the majority of subgroups, the current policy of preventive therapy in those with positive TST was the most cost-effective. Nevertheless, our analysis determined that LTBI treatment is not cost-effective in nonhousehold Canadian-born (nonaboriginal) or foreign-born contacts age > or = 10 y/o. On the other hand, empirical treatment without screening of all non-BCG-vaccinated household contacts age < 10 y/o appeared cost-effective. Such an optimal approach would result in an incremental net monetary benefit of $25 for each contact investigated for a willingness-to-pay of $50,000/QALY. Results were robust to several alternative assumptions considered in sensitivity analyses.

Conclusions: The current practice of LTBI treatment for TB contacts with a TST size > or = 5 mm is cost-effective. A customized approach based on excluding low risk groups from screening and providing treatment to high risk contacts without screening could improve the performance of the program.

MeSH terms

  • Adolescent
  • Adult
  • Antitubercular Agents / economics*
  • Antitubercular Agents / therapeutic use
  • British Columbia / epidemiology
  • Child
  • Child, Preschool
  • Contact Tracing / economics*
  • Cost-Benefit Analysis
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Markov Chains
  • Models, Economic
  • Quality-Adjusted Life Years
  • Risk Factors
  • Sensitivity and Specificity
  • Tuberculin Test
  • Tuberculosis, Pulmonary / drug therapy
  • Tuberculosis, Pulmonary / economics*
  • Tuberculosis, Pulmonary / epidemiology
  • Tuberculosis, Pulmonary / transmission
  • Young Adult


  • Antitubercular Agents